# Lakefront Biotherapeutics NV (LKFT)

> Source: Nexqual · https://nexqual.com/LKFT · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Lakefront Biotherapeutics NV (LKFT), nexqual.com/LKFT" · informational, not investment advice.

**Price:** USD 31.4 (+2.68% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 30.58 · day 30.55–31.53 · 52w 25.68–36.24 · market cap $2.06B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold LKFT (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 30.42 (range 21.28–44.04).
- Total return with dividends: 1Y -2.0% vs S&P 500 +14.9%; 5Y -38.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD 0.23, revenue estimate $41.2M.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold LKFT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Einhorn | Greenlight Capital | 0.37% | $14.5M | Unchanged |

## Analysts
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 30.42 (low 21.28, high 44.04).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | RBC Capital | Upgrade | Sector Perform → Outperform | $26 → $45 |
| 2026-08-11 | Morgan Stanley | Target lowered | Equal-Weight | $30 → $26 |
| 2026-08-11 | RBC Capital | Target lowered | Sector Perform | $28 → $26 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -2.0% | -38.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -2.0% | -9.2% |
| Volatility (annualized) | 27.9% | 31.2% |
| Max drawdown | -24.7% (Jan 2026→Aug 2026) | -67.5% (Apr 2022→Feb 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/LKFT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in LKFT's own 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/glpg-20251231x20f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Alfasigma | "Effective January 31, 2024, following the closing of the transaction between us and Alfasigma S.p.A. to transfer the Jyseleca® business to Alfasigma S.p.A., we assigned our rights and obligations under the filgotinib col…" |
| Partner | USWM CT | "Following our decision to initiate the wind-down of the cell therapy activities, we have notified USWM of our decision to terminate the Collaboration and Exclusive License Agreement and all ancillary agreements." |
| Partner | AbbVie (ABBV) | "In this role, he oversaw complex mergers, acquisitions, licensing, and collaborations, including AbbVie's landmark $63 billion acquisition of Allergan PLC and numerous high-profile partnerships with companies such as Boe…" |
| Partner | Lonza | "As a result, we fully impaired all associated intangible assets (with a total net book value at September 30, 2025 of €131.5 million), consisting of the in-process R&D (€28.2 million related to two CAR-T product candidat…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.23 | $-1.31 | -117.6% | $41.2M | 1 |
| Next quarter (ends 2026-12-31) | $-0.17 | $-0.71 | -76.9% | $106.8M | 2 |
| Current fiscal year (ends 2026-12-31) | $-0.71 | $-13.24 | -94.6% | $117.2M | 1 |
| Next fiscal year (ends 2027-12-31) | $-1.06 | $-1.72 | -38.2% | $84.6M | 2 |